FilingReader Intelligence
China Resources Double Crane gets FDA trial approval
July 29, 2025 at 09:11 AM UTC•By FilingReader AI
China Resources Double Crane Pharmaceutical's subsidiary received US FDA approval for clinical trials of DC50292A tablets, designed to treat advanced solid tumors.
The company has invested 41.66 million yuan in developing the drug, which remains in early-stage clinical development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600062•Shanghai Stock Exchange
News Alerts
Get instant email alerts when China Resources Double Crane Pharmaceutical publishes news
Free account required • Unsubscribe anytime